GLPwatch
Papers (9189)
Page 130 of 154, ranked by citation count.
- Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
- Depot-specific differences and heterogeneity of adipose-derived stem cells in diet-induced obesity.
- Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.
- [Comments on current guidelines of type 2 diabetes mellitus treatment].
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
- Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials.
- Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists.
- Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide.
- Tandem mass tag-based proteomic profiling revealed potential therapeutic targets and mechanisms of liraglutide for the treatment of impaired glucose tolerance.
- [Exendin-4 promotes paracrine action of adipose-derived stem cells through PI3K/Akt signaling pathways].
- Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus .
- Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission.
- Cost effectiveness analysis of six non insulin agents for type 2 diabetes in Iran using a patient level simulation with UKPDS OM2.
- Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.
- Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.
- Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
- Impact of degradation in subcutaneous tissue and lymphatic fluid on absorption of Fc-fusion proteins following subcutaneous administration.
- Semaglutide: FDA publishes warning amid reports of patients overdosing.
- A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.
- Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
- Treatment of persistent or recurrent type 2 diabetes after metabolic surgery.
- IDegLira: combining efficacy, durability, and convenience?
- Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists.
- iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.
- Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles.
- ADDITION OF DULAGLUTIDE FOR A HIGH-DOSE INSULIN REQUIRING PATIENT WITH TYPE 2 DIABETES MELLITUS: A REMARKABLE RESPONSE.
- Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease.
- Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes.
- A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.
- An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update.
- IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
- Semaglutide and Cardiovascular Outcomes.
- [Rare cause of insufficient metabolic control of diabetes mellitus - Case 10/2011].
- Current challenges in type 2 diabetes.
- Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
- Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.
- WEIGHT LOSS IN A YOUNG PATIENT WITH TYPE 2 DIABETES: CHALLENGES OF DIABETES MANAGEMENT USING ONLINE PROGRAM OF GOOD NUTRITION (CASE REPORT).
- New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
- [Pharmacotherapy for obesity].
- Reply: <sup>68</sup>Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
- Bone morphogenetic protein-9 maybe an important factor which improves insulin resistance in PCOS.
- Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.
- [Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].
- Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
- Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.
- Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview.
- Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
- The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).
- Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.
- Unremitting Nausea Due to Lurasidone After Semaglutide Initiation.
- [Effects of exenatide lar in type 2 diabetes mellitus and obesity].
- The incretin system in the management of type 2 diabetes mellitus.
- Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study.
- Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
- Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
- Activation of GLP-1R ameliorates microglial pyroptosis after spinal cord injury by restoring FANCC expression.
- [Pharmacotherapy of obesity in Germany].
- Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database.